StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.32+0.02 (+1.54%)

Close on Nov 20, 2026Market cap $184.19MP/E –Yield –

Inhibikase Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Inhibikase Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$42.61M. For fiscal 2025 it was -$27.80M. The highest annual figure on record is -$14.30M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.80M–
FY2024Dec 31, 2024-$19.15M–
FY2023Dec 31, 2023-$18.10M–
FY2022Dec 31, 2022-$17.59M–
FY2021Dec 31, 2021-$14.30M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.44M–
Q1 FY2026Mar 31, 2026-$12.06M–
Q4 FY2025Dec 31, 2025-$7.52M–
Q3 FY2025Sep 30, 2025-$10.59M–
Q2 FY2025Jun 30, 2025-$5.57M–
Q1 FY2025Mar 31, 2025-$4.12M–
Q4 FY2024Dec 31, 2024-$5.35M–
Q3 FY2024Sep 30, 2024-$4.88M–
Q2 FY2024Jun 30, 2024-$5.05M–
Q1 FY2024Mar 31, 2024-$3.87M–
Q4 FY2023Dec 31, 2023-$3.44M–
Q3 FY2023Sep 30, 2023-$4.11M–
Q4 FY2022Dec 31, 2022-$3.56M–
Q3 FY2022Sep 30, 2022-$5.70M–

More Inhibikase Therapeutics figures

See a number that looks wrong?